Serotonin-2 Receptors and Human Sleep: Effect of a Selective Antagonist on EEG Power Spectra

To investigate the effect on the sleep EEG, a 1-mg oral dose of SR 46349B, a novel 5-HT2 antagonist, was administered three hours before bedtime. The drug enhanced slow wave sleep (SWS) and reduced stage 2 without affecting subjective sleep quality. In nonREM sleep (NREMS) EEG slow-wave activity (SW...

Full description

Saved in:
Bibliographic Details
Published inNeuropsychopharmacology (New York, N.Y.) Vol. 21; no. 3; pp. 455 - 466
Main Authors Landolt, Hans-Peter, Meier, Viola, Burgess, Helen J., Finelli, Luca A., Cattelin, Françoise, Achermann, Peter, Borbély, Alexander A.
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.09.1999
Nature Publishing
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To investigate the effect on the sleep EEG, a 1-mg oral dose of SR 46349B, a novel 5-HT2 antagonist, was administered three hours before bedtime. The drug enhanced slow wave sleep (SWS) and reduced stage 2 without affecting subjective sleep quality. In nonREM sleep (NREMS) EEG slow-wave activity (SWA; power within 0.75–4.5 Hz) was increased and spindle frequency activity (SFA; power within 12.25–15 Hz) was decreased. The relative NREMS power spectrum showed a bimodal pattern with the main peak at 1.5 Hz and a secondary peak at 6 Hz. A regional analysis based on bipolar derivations along the antero-posterior axis revealed significant ‘treatment’ × ‘derivation’ interactions within the 9–16 Hz range. In enhancing SWA and attenuating SFA, the 5-HT2 receptor antagonist mimicked the effect of sleep deprivation, whereas the pattern of the NREMS spectrum differed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0893-133X
1740-634X
DOI:10.1016/S0893-133X(99)00052-4